Skip to main
LQDA
LQDA logo

LQDA Stock Forecast & Price Target

LQDA Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 67%
Buy 22%
Hold 0%
Sell 11%
Strong Sell 0%

Bulls say

Liquidia Corp has demonstrated a strong financial outlook, underscored by an increase in sales estimates for its product YUTREPIA (treprostinil) inhalation powder, now projected to reach peak sales of $1.7 billion to $2 billion due to stronger than expected market uptake. The company's successful initial launch has contributed to its operating profitability in the first full quarter of Yutrepia's introduction, with a significant sales figure of $18.8 million reported. Additionally, the growing patient conversion rate and improved six-minute walk distance (6MWD) results further enhance the company's prospects in addressing unmet patient needs within the pulmonary hypertension market.

Bears say

Liquidia Corp faces considerable legal risks that may threaten the exclusivity of YUTREPIA, its primary revenue source, which contributes to a negative outlook on the stock. The ongoing legal challenges concerning patent rights could adversely affect YUTREPIA's market operation, resulting in significant downside risk should the company not succeed in these cases. Additionally, a decline in R&D expenditures indicates a shift away from developmental initiatives, potentially undermining future growth and operational stability, further compounded by fears of achieving peak commercial revenue and securing necessary capital for ongoing operations.

LQDA has been analyzed by 9 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 22% recommend Buy, 0% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Liquidia Technologies Inc (LQDA) Forecast

Analysts have given LQDA a Buy based on their latest research and market trends.

According to 9 analysts, LQDA has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Liquidia Technologies Inc (LQDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.